ArticleFuture oncology (London, England)2025

Osimertinib before and after chemoradiotherapy for unresectable stage III EGFR-mutated NSCLC: NEOLA Trial Protocol.

Jacqueline V Aredo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.